Li Yu - 24 Jun 2021 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
VP Cntrllr/Prncpl Acctng Offcr
Signature
/s/ Li Yu
Issuer symbol
OCX
Transactions as of
24 Jun 2021
Transactions value $
$0
Form type
4
Filing time
14 Oct 2021, 16:05:25 UTC
Previous filing
24 May 2021
Next filing
17 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +160K $0.00 160K 24 Jun 2021 Common Stock 160K $4.33 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option award was granted on May 18, 2021, but such award was subject to shareholder approval of an increase in the number of shares available for issuance under the Oncocyte 2018 Equity Incentive Plan. Such shareholder approval was received on June 24, 2021.
F2 25% of the options will become exercisable after one year of continuous employment from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continued employment on the applicable vesting date.